Opko Ireland Global Holdings, Limited

Eirgen Pharma Ltd.

Opko Renal, LLC

Queen's University at Kingston

Cytochroma Inc.

Proventiv Therapeutics, LLC

Other

Opko IP Holdings Ii, Inc.

Samir P Tabash

Jay A White

P Martin Petkovich

Charles W Bishop

Sammy Asiamah Agudoawu

Joel Z Melnick

Eric J Messner

Keith H Crawford

Stephen A Strugnell

Susan Peers

R Stephen Brown

Igor S Kozin

Arthur N Ley

Raymond J Bowers

Kevin R Hall

John G St Marseille

Robin A Wynne-Edwards

Peter V Hodson

Moe Hussain

Eric J P Marcotte

Christian F Helvig

Susan H Peers

Parveen Akhtar

Sammy A Agudoawu

John G Stmarseille

Eric J-P Marcotte

A stabilized formulation for controlled release of a vitamin D compound is disclosed. The formulation can comprise one or both of 25-hydroxyvitamin Dand 25-hydroxyvitamin Dand a stabilizing compound. The stabilized formulations exhibit a stable dissolution profile following exposure to storage conditions and demonstrate improved pharmacokinetic parameters compared to unstabilized formulations.

Stabilized modified release vitamin D formulation and method of administering same

The invention relates to methods and compositions for reducing toxicity associated with administration of vitamin D3, its 25-hydroxylated and 1-hydroxylated forms, and analogs thereof.

Method of treating vitamin D insufficiency and deficiency

Methods, compositions, and kits for adjunctive therapy using 25-hydroxyvitamin D are disclosed. The 25-hydroxyvitamin D may be administered with an agent that increases the risk of hypocalcemia, such as cinacalcet or a salt thereof, and/or an anticancer agent. The adjunctive therapy is effective to treat and prevent iatrogenic hypocalcemia and/or secondary hyperparathyroidism, as well as delay cancer progression and the time to a post-treatment skeletal related event.

Adjunctive therapy with 25-hydroxyvitamin D and articles therefor

Methods and compositions for reducing serum parathyroid levels in, for example, chronic kidney disease patients are disclosed. In these methods, an effective amount of a modified release formulation of 25-hydroxy vitamin D is orally administered to a patient suffering from secondary hyperparathyroidism to lower the patient's serum intact parathyroid hormone (iPTH) level, while avoiding a surge in serum total 25-hydroxy vitamin D.

Methods and compositions for reducing parathyroid levels

A stabilized formulation for controlled release of a vitamin D compound is disclosed. The formulation comprises one or both of 25-hydroxyvitamin Dand 25-hydroxyvitamin Dand a cellulosic compound. The stabilized formulations exhibit a stable dissolution profile following exposure to storage conditions and demonstrate improved pharmacokinetic parameters compared to unstabilized formulations.

Stabilized modified release Vitamin D formulation and method of administering same

A stable, controlled release formulation for oral dosing of vitamin D compounds is disclosed. The formulation is prepared by incorporating one or more vitamin D compounds into a solid or semi-solid mixture of waxy materials. Oral dosage forms can be prepared by melt-blending the components described herein and filling gelatin capsules with the formulation.

Methods for controlled release oral dosage of a vitamin D compound

Method for treating secondary hyperparathyroidism in CKD

Growing community of inventors

Whitby, Canada

Samir P Tabash